Migraine trials recruiting in Wisconsin

All Migraine trials nationally

Cities in Wisconsin

Recruiting trials in Wisconsin

• A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine
  NCT07018713 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Wisconsin: La Crosse
• A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine
  NCT07018700 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Wisconsin: La Crosse
• A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine
  NCT07674654 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Wisconsin: Kenosha
• A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine
  NCT05164172 · Phase: Phase 3 · Ages: 6 Years to 17 Years · Sex: All (male and female) · Wisconsin: Milwaukee
• A Study of Eptinezumab in Pediatric Participants With Episodic Migraine
  NCT05897320 · Phase: Phase 3 · Ages: 6 Years to 17 Years · Sex: All (male and female) · Wisconsin: Milwaukee
• A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine
  NCT07645924 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · Wisconsin: Kenosha
• A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic Migraine
  NCT06602479 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · Wisconsin: Mequon
• Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study
  NCT06972056 · Phase: Phase 4 · Ages: 18 Years to 70 Years · Sex: All (male and female) · Wisconsin: Marshfield, Milwaukee
• Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine
  NCT04743141 · Phase: Phase 3 · Ages: 6 Years to 17 Years · Sex: All (male and female) · Wisconsin: Madison
• Randomized Study in Children and Adolescents With Migraine: Acute Treatment
  NCT04649242 · Phase: Phase 3 · Ages: 6 Years to 17 Years · Sex: All (male and female) · Wisconsin: Kenosha, Madison
• Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
  NCT05125302 · Phase: Phase 3 · Ages: 6 Years to 17 Years · Sex: All (male and female) · Wisconsin: Mequon
• Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research
  NCT04806620 · Phase: Not specified · Ages: 2 Years and older · Sex: All (male and female) · Wisconsin: Delafield